VCEL logo

VCEL Vericel Corporation

NASDAQ Capital Market · Biotechnology · Healthcare

$57.48
+0.52 (+0.91%)

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending…

Market Cap: $2.93Bvcel.com

Price

No data yet.

Social Signal Score

59
5d
—
30d
60
4 mentions
—
60d
58
5 mentions
—
90d
60
8 mentions
—
news: 8

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 5Sell 0Strong Sell 0
Avg price target$62.5+8.7%
Low $60Median $62.5High $65
Current Consensus

Revenue

$85.37M+416.68%
$9.36M$37.21M$65.07M$92.92M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.27
$0.18–$0.39
5 analysts
FY2026
$0.76+185% YoY
$0.71–$0.78
5 analysts
FY2027
$0.94+25% YoY
$0.86–$1.10
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Dominick C. Colangelo
Sector
Healthcare
Industry
Biotechnology
Employees
398
Beta
1.06
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
13.62
vcel.com